Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Real-World Utilization of Midostaurin Among Patients with Systemic Mastocytosis (SM)

Ajeet Gajra, MD FACP, Andrew J Klink, PhD MPH, Dhruv Chopra, MS, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 5378.

https://doi.org/10.1182/blood-2019-131028

Published: 2019

Journal Articles

The CDK4/6 Inhibitor Palbociclib Exerts Growth-Inhibitory Effects on Neoplastic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest

Mathias A. Schneeweiss, Gabriele Stefanzl, Daniela Berger, Gregor Eisenwort, Mohamad Jawhar, Greiner Georg, MD PhD, Gregor Hoermann, Wolfgang R. Sperr, Michel Arock, Andreas Reiter, MD, Peter Valent, Karoline V. Gleixner, MD

Blood (2018) 132 (Supplement 1): 1363.

https://doi.org/10.1182/blood-2018-99-116525

Published: 2018

Journal Articles

Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (AdvSM)

Daniel J. DeAngelo, MD, Albert Thomas Quiery, MD, Deepti Radia, MD, Mark W Drummond, MB ChB, PhD FRCPath, Jason Gotlib, MD, William A Robinson, MD PhD, Elizabeth Hexner, MDMS, Srdan Verstovsek, MD PhD, Hongliang Shi, Terri Alvarez-Diez, Oleg Schmidt-Kittler, Erica Evans, PhD, Mary Ellen Healy, Beni B. Wolf, MD PhD, Michael W. Deininger, MD PhD

Blood (2017) 130 (Supplement 1): 2.

https://doi.org/10.1182/blood.V130.Suppl_1.2.2

Published: 2017

Journal Articles

SETD2 Non-Genomic Loss of Function and p53 Functional Inactivation in Advanced Systemic Mastocytosis (SM): Pathogenetic and Therapeutic Implications

Blood (2017) 130 (Supplement 1): 2944.

https://doi.org/10.1182/blood.V130.Suppl_1.2944.2944

Published: 2017

Journal Articles

Phase 2 Study of Brentuximab Vedotin in Patients with Advanced Systemic Mastocytosis

John H. Baird, Srdan Verstovsek, MD PhD, Tracy I. George, Isabel Reyes, Justin Abuel, Cecelia Perkins, Cheryl Langford, Kurt Schroeder, Jason Gotlib, MD

Blood (2017) 130 (Supplement 1): 2909.

https://doi.org/10.1182/blood.V130.Suppl_1.2909.2909

Published: 2017

Journal Articles

Aleukemic Mast Cell Leukemia (aMCL) - Clinical Characteristics and Outcomes

Preetesh Jain, MBBS, MDDM, PhD, Sa Wang, MD, Hagop M. Kantarjian, MD, Nawid Sarwari, Keyur P. Patel, MD PhD, Prithviraj Bose, MD, Sherry Pierce, BSN, BA, Tapan M. Kadia, MD, Naval Daver, MD, Naveen Pemmaraju, MD, Jorge E. Cortes, MD, Srdan Verstovsek, MD PhD

Blood (2016) 128 (22): 4255.

https://doi.org/10.1182/blood.V128.22.4255.4255

Published: 2016

Journal Articles

Preliminary Safety and Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (SM)

Mark W. Drummond, PhD MD, Daniel J. DeAngelo, MD PhD, Michael W. Deininger, MD PhD, Deepti Radia, MBBS, MRCPI, FRCPath MSc, MD, Albert Thomas Quiery, MD, Elizabeth O Hexner, MD, Hongliang Shi, MS, Terri Alvarez-Diez, PhD, Erica K. Evans, PhD, Mary Ellen Healy, MS, Beni B. Wolf, MD PhD, Srdan Verstovsek, MD PhD

Blood (2016) 128 (22): 477.

https://doi.org/10.1182/blood.V128.22.477.477

Published: 2016

Journal Articles

Clonal Evolution Revealed By Exome Sequencing in a Case of Primary Myelofibrosis Associated with Subsequent Development of Aggressive Systemic Mastocytosis/Mast Cell Leukemia

Stephen T. Oh, MD PhD, Christopher A. Miller, PhD, Yevgeniy Gindin, PhD, Taylor M. Brost, Jason Chan, MD PhD, Mary C. Fulbright, Daniel A.C. Fisher, PhD, Eric J. Duncavage, MD, Michelle O'Laughlin, Malachi Griffith, PhD, Obi L. Griffith, PhD, Lukas D. Wartman, MD

Blood (2016) 128 (22): 5496.

https://doi.org/10.1182/blood.V128.22.5496.5496

Published: 2016

Journal Articles

Role of LIM Kinase in Oncogenic Signaling from FLT3 and KIT Receptors and Its Targeting in Myeloid Leukemia

Ruchi Pandey, PhD, Raghuveer Mali, PhD, Anindya Chatterjee, MS,PhD, Fabrice Paublant, Renaud Prudent, Laurence Lafanechere, Reuben Kapur, PhD

Blood (2015) 126 (23): 1257.

https://doi.org/10.1182/blood.V126.23.1257.1257

Published: 2015

Journal Articles

Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis

Blood (2015) 126 (23): 4085.

https://doi.org/10.1182/blood.V126.23.4085.4085

Published: 2015

Journal Articles

Novel Mechanisms of Growth Inhibition By Histone Deacetylase Inhibitors in MPN

Ruchi Pandey, PhD, Raghuveer Mali, PhD, Baskar Ramdas, PhD, Reuben Kapur, PhD

Blood (2015) 126 (23): 1633.

https://doi.org/10.1182/blood.V126.23.1633.1633

Published: 2015

Journal Articles

Mast Cell Disease and Blood Coagulation Abnormalities: Discussion on 14 Cases and Review of the Literature

Ana Carvalhosa, Gandhi Damaj, MD PhD, Danielle Canioni, MD, Laure Cabaret, Nathalie Costédoat-Chalumeau, MD PhD, Pascal Cathebras, MD, Stéphane Durupt, MD, Isabelle Durieu, MD PhD, Emmanuel Gyan, MD PhD, David Launay, MD PhD, Benoit Pilmis, MD, Laurent Frenzel, MD, Olivier Lortholary, MD PhD, Olivier Hermine, MD PhD, Cedric R. Hermans, MD PhD, Marie-Olivia Chandesris, MD

Blood (2014) 124 (21): 2856.

https://doi.org/10.1182/blood.V124.21.2856.2856

Published: 2014

Journal Articles

Ectopic Expression of Lin28 Biases Myeloid Differentiation to Promote an Immature Mast Cell State and Is Implicated in Aggressive Mastocytosis

Leo D. Wang, MDPhD, Phi Nguyen, Robert G Rowe, MD PhD, Tata Nageswara Rao, PhD, George Q. Daley, MD PhD, Amy J. Wagers, PhD

Blood (2014) 124 (21): 5571.

https://doi.org/10.1182/blood.V124.21.5571.5571

Published: 2014

Journal Articles

Familial Mastocytosis: Identification Of KIT K509I Mutation and Its In Vitro Sensitivity To Imatinib, Dasatinib and PKC412

Paula De Melo Campos, MD, João Agostinho Machado-Neto, MSc, Adriana Silva Santos Duarte, PhD, Renata Scopim-Ribeiro, BSc, Flavia Fonseca de Carvalho Barra, MD, José Vassallo, MD, PhD, Irene Lorand-Metze, MD, PhD, Ramon V. Tiu, MD, Fernando Ferreira Costa, MD, PhD, Sara T O Saad, MD, PhD, Fabiola Traina, M.D., Ph.D.

Blood (2013) 122 (21): 5267.

https://doi.org/10.1182/blood.V122.21.5267.5267

Published: 2013

Journal Articles

Mast cell leukemia

Sophie Georgin-Lavialle, Ludovic Lhermitte, Patrice Dubreuil, Marie-Olivia Chandesris, Olivier Hermine, Gandhi Damaj

Blood (2013) 121 (8): 1285–1295.

https://doi.org/10.1182/blood-2012-07-442400

Published: 2013

Journal Articles

KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial

Jason Gotlib, MD, MS, Hanneke C. Kluin-Nelemans, MD, PhD, Tracy I. George, MD, Cem Akin, MD, PhD, Karl Sotlar, MD, Olivier Hermine, MD, PhD, Farrukh Awan, MD, MS, Elizabeth Hexner, MD, Michael J. Mauro, MD, Rodica Morariu, MD, Margaret Squier, MD, PhD, Matthieu Villeneuve, Fabienne Emery-Salbert, MSc, Karin Hartmann, MD, Hans-Peter Horny, MD, Peter Valent, MD, Andreas Reiter, MD

Blood (2012) 120 (21): 799.

https://doi.org/10.1182/blood.V120.21.799.799

Published: 2012

Journal Articles

Development and Validation of a Sensitive Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Assay for the Simultaneous Quantification of Midostaurin (PKC412) and Its Two Major Metabolites: A Suitable Tool for the Monitoring of the Drug in Patients Suffering From Advanced Systemic Mastocytosis

Philippe Bourget, MD, PhD, Marie-Olivia Chandesris, MD, Alexandre Amin, Fabrice Vidal, Christophe Merlette, Isabelle Hirsh, Ana Carvalhosa, Agnes Mogenet, Christine Broissand, MD, Bérénice Giraud, Laurent Frenzel, Gandhi Damaj, Olivier Lortholary, MD, PhD, Olivier Hermine, MD, PhD

Blood (2012) 120 (21): 4913.

https://doi.org/10.1182/blood.V120.21.4913.4913

Published: 2012

Journal Articles

Effects of Ponatinib and Other Novel TKI On Growth, Survival, and Function of Neoplastic Eosinophils Carrying FIP1L1/Pdgfra

Irina Sadovnik, M.Sc., Peter Valent, MD, Els Lierman, PhD, Harald Herrmann, M.D., Barbara Peter, D.V.M., Verena Suppan, BSc, Gabriele Stefanzl, MSc, Winfried F Pickl, MD, Jan Cools, PhD, Peter Vandenberghe, MD, PhD

Blood (2012) 120 (21): 1760.

https://doi.org/10.1182/blood.V120.21.1760.1760

Published: 2012

Journal Articles

Burden of Illness of Aggressive Systemic Mastocytosis (ASM)

Michelle L Sotak, MPH, MBA, Mihaela Marin, MD, MSc, John Coombs, PharmD, MBA, April Teitelbaum, MD, MS

Blood (2011) 118 (21): 4755.

https://doi.org/10.1182/blood.V118.21.4755.4755

Published: 2011

Journal Articles

5-Azacytidine and Decitabine Induce FAS Re-Expression, Exert Major Proapoptotic Effects, and Cooperate with the FAS Ligand in Producing Apoptosis in Neoplastic Human Mast Cells,

Viviane Ghanim, M.D., Harald Herrmann, MD, Emir Hadzijusufovic, DVM, Barbara Peter, D.V.M., Katharina Blatt, M.Sc., Karina Schuch, Sabine Cerny-Reiterer, D.V.M., Irina Mirkina, PhD, Gerwin Heller, PhD, Sabine Zöchbauer-Müller, MD, Heidrun Karlic, PhD, Winfried F Pickl, MD, Peter Valent, M.D.

Blood (2011) 118 (21): 3457.

https://doi.org/10.1182/blood.V118.21.3457.3457

Published: 2011

NARROW

Real-World Utilization of Midostaurin Among Patients with Systemic Mastocytosis (SM)

The CDK4/6 Inhibitor Palbociclib Exerts Growth-Inhibitory Effects on Neoplastic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest

Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (AdvSM)

SETD2 Non-Genomic Loss of Function and p53 Functional Inactivation in Advanced Systemic Mastocytosis (SM): Pathogenetic and Therapeutic Implications

Phase 2 Study of Brentuximab Vedotin in Patients with Advanced Systemic Mastocytosis

Aleukemic Mast Cell Leukemia (aMCL) - Clinical Characteristics and Outcomes

Preliminary Safety and Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (SM)

Clonal Evolution Revealed By Exome Sequencing in a Case of Primary Myelofibrosis Associated with Subsequent Development of Aggressive Systemic Mastocytosis/Mast Cell Leukemia

Role of LIM Kinase in Oncogenic Signaling from FLT3 and KIT Receptors and Its Targeting in Myeloid Leukemia

Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis

Novel Mechanisms of Growth Inhibition By Histone Deacetylase Inhibitors in MPN

Mast Cell Disease and Blood Coagulation Abnormalities: Discussion on 14 Cases and Review of the Literature

Ectopic Expression of Lin28 Biases Myeloid Differentiation to Promote an Immature Mast Cell State and Is Implicated in Aggressive Mastocytosis

Familial Mastocytosis: Identification Of KIT K509I Mutation and Its In Vitro Sensitivity To Imatinib, Dasatinib and PKC412

Mast cell leukemia

KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial

Effects of Ponatinib and Other Novel TKI On Growth, Survival, and Function of Neoplastic Eosinophils Carrying FIP1L1/Pdgfra

Burden of Illness of Aggressive Systemic Mastocytosis (ASM)

5-Azacytidine and Decitabine Induce FAS Re-Expression, Exert Major Proapoptotic Effects, and Cooperate with the FAS Ligand in Producing Apoptosis in Neoplastic Human Mast Cells,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only